The BOLERO 4 study NCT01698918 is a currently ongoing trial evaluating the use of everolimus in combination with letrozole as first line therapy for postmenopausal women with hormone receptor positive, HER2 negative metastatic breast cancer
nolvadex pct dose 5 with control A, C, D, F, H J or Pax6 expressing B, C, E, F J plasmid see Fig 2B